Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses
A partir d'une revue systématique de la littérature publiée entre 1996 et 2012 (29 études), cette étude évalue le rapport coût-efficacité des thérapies innovantes pour traiter les cancers hématologiques
We analyzed cost-effectiveness studies related to hematologic malignancies from the Tufts Cost-Effectiveness Analysis Registry (www.cearegistry.org), focusing on studies of innovative therapies. Studies that met inclusion criteria were categorized by four cancer types (chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and multiple myeloma (MM)) and nine treatment agents (
α interferon, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, lenalidomide, rituximab alone or in combination, and thalidomide). We examined study characteristics and stratified cost-effectiveness ratios by type of cancer, treatment, funder, and year of study publication. Twenty-nine studies published 1996-2012 (including 44 cost-effectiveness ratios) met inclusion criteria, twenty-two (76%) of which were industry-funded. Most ratios fell below $50,000/QALY (73%) and $100,000/QALY (86%). Industry-funded studies (n=22) reported a lower median ratio ($26,000/QALY) than others (n=7) ($33,000/QALY), although the difference was not statistically significant. Published data suggest innovative treatments for hematologic malignancies may provide reasonable value for money.